Hyperion DeFi, Inc. (HYPD)
NASDAQ: HYPD · Real-Time Price · USD
14.36
-1.46 (-9.23%)
At close: Jul 3, 2025, 1:00 PM
14.04
-0.32 (-2.23%)
After-hours: Jul 3, 2025, 4:59 PM EDT

Company Description

Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States.

The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals.

Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025.

Hyperion DeFi, Inc. was founded in 2014 and is based in New York, New York.

Hyperion DeFi, Inc.
Country United States
Founded 2014
IPO Date Jan 25, 2018
Industry Medical Devices
Sector Healthcare
Employees 14
CEO Michael Rowe

Contact Details

Address:
295 Madison Avenue, Suite 2400
New York, New York 10017
United States
Phone 917 289 1117
Website eyenovia.com

Stock Details

Ticker Symbol HYPD
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001682639

Key Executives

Name Position
Michael Rowe Chief Executive Officer
Michael Rowe Chief Financial Officer
Bren Kern Chief Operating Officer

Latest SEC Filings

Date Type Title
Jul 2, 2025 SCHEDULE 13D/A Filing
Jul 2, 2025 8-K Current Report
Jun 27, 2025 424B5 Filing
Jun 27, 2025 8-K Current Report
Jun 24, 2025 8-K Current Report
Jun 20, 2025 SCHEDULE 13D/A Filing
Jun 13, 2025 SCHEDULE 13D/A Filing
Jun 5, 2025 8-K Current Report
Jun 3, 2025 SCHEDULE 13D/A Filing
Jun 2, 2025 424B5 Filing